CBS 2019
CBSMD教育中心
English

DAPT Duration

科研文章

荐读文献

Elaborately Engineering a Self-Indicating Dual-Drug Nanoassembly for Site-Specific Photothermal-Potentiated Thrombus Penetration and Thrombolysis Comparison of 1-month Versus 12-month Dual Antiplatelet Therapy after Implantation of Drug-eluting Stents Guided by either Intravascular Ultrasound or Angiography in Patients with Acute Coronary Syndrome: Rationale and Design of Prospective, Multicenter, Randomized, Controlled IVUS-ACS & ULTIMATE-DAPT trial 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Dual Antiplatelet Therapy Duration in Medically Managed Acute Coronary Syndrome Patients: Sub-Analysis of the OPT-CAD Study Antibody-Based Ticagrelor Reversal Agent in Healthy Volunteers 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: Insights from the randomized GLOBAL LEADERS trial Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies Dual Antiplatelet TherapyIs It Time to Cut the Cord With Aspirin? Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI

Clinical Trial2010 Nov;340(5):356-9.

JOURNAL:Am J Med Sci. Article Link

Respiratory syncytial virus infection and risk of acute myocardial infarction

Guan XR, Jiang LX, Ma XH et al. Keywords: Respiratory syncytial virus, Infection, Acute myocardial infarction

ABSTRACT


INTRODUCTION - Increasing evidences have shown that pathogens may promote atherosclerosis and trigger acute myocardial infarction (AMI). There is no report on the association between respiratory syncytial virus (RSV) infection and AMI. The case-control study was used to assess the association of previous RSV infection and acute myocardial infarction.


METHODS - AMI cases and non-AMI controls were recruited from patients at a large teaching hospital in Harbin, China, during October 1, 2005, to March 31, 2006, and October 1, 2006, to March 31, 2007. Questionnaire survey was conducted to collect information on demographic characteristics and heart disease risk factors. Fasting blood sample was obtained to measure immunoglobulin G antibodies to RSV, Cytomegalovirus, herpes simplex virus type-1 and type-2, adenovirus, Rubella virus, Chlamydia pneumoniae and Helicobacter pylori and to measure the level of cholesterol, fasting serum glucose, triglycerides and high-sensitivity C-reactive protein.

RESULTS - AMI group had more smokers than controls (56.9% versus 18.0%) and were more likely to have positive immunoglobulin G antibodies to RSV (OR, 6.2; 95% CI, 3.5-10.7; P < 0.001). After adjustment for potential confounding variables, the association between RSV and AMI remained (adjusted odds ratio, 11.1; 95% confidence interval, 3.3-29.5).

CONCLUSIONS - Our study supported the hypothesis that the previous RSV infection was associated with AMI. This indicates that prevention and proper treatment of RSV infection are of great clinical importance for the reduction of AMI risk.